ENROLLMENT
71%
142 / 200 patients
BUDGET
60%
$2.5M /$ $4.2M
SCREEN FAILURES
16.5%
vs 18.0% benchmark
ACTIVE SITES
2
5.0 total FTE
MILESTONES
2/5
40% complete
ENROLLMENT TRENDS
No projection data available
BUDGET BREAKDOWN
TOTAL BUDGET
$4.20M
CONSUMED
$2.52M
60%
REMAINING
$1.68M
+3% INF$1.73M
Passthrough
$1.60M (38%)
38%
Investigator Fees
$1.00M (24%)
24%
Consumed
$2.52M (60%)
60%
Remaining
$1.68M (40%)
40%
AVG COST PER PATIENT
$21,000
CURRENT BURN RATE
$17,746.479/pt
SITE PERFORMANCE
| SITE | STATUS | ENROLLMENT | TARGET | PROGRESS | SCREEN FAIL | FTE |
|---|---|---|---|---|---|---|
Nashville | 78 | 100 | 78% | 16.1% | 2.5 | |
Memphis | 64 | 100 | 64% | 16.9% | 2.5 |
RISK REGISTER
MEDIUM PRIORITY (1)
9
Competing trial opened at nearby academic center
P:3 × I:3 • ENROLLMENT
MILESTONES
First Patient Enrolled
Target: 6/10/2024 • Completed: 6/8/2024
50% Enrollment
Target: 3/1/2025 • Completed: 2/15/2025
75% Enrollment
Target: 9/1/2025
Last Patient Enrolled
Target: 1/31/2026
Database Lock
Target: 6/30/2026
TRIAL INFORMATION
Protocol Version:2.0
Sponsor:HeartBio Sciences
Therapeutic Area:Cardiology
Start Date:6/1/2024
Est. Completion:6/30/2026
Passthrough:$1.60M
Per Patient:$8,000
Investigator Fees:$5,000/pt